ARWR
Arrowhead Pharmaceuticals Inc
66.10$
-1.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -77.9% | -100.0% | – | – | -89.4% | +21,608.4% | -94.9% | +823.7% | +2.9% | -72.1% | +2.1% | – | |
| – | +10.5% | +6.1% | +5.7% | +5.1% | +4.2% | +16.2% | +2.3% | +2.6% | +0.1% | -0.3% | – | – | |
| – | -105.8% | – | – | – | – | +21,608.4% | -94.9% | +823.7% | +2.9% | -72.1% | +2.1% | – | |
| – | +16.8% | -13.9% | +52.7% | -11.3% | +4.3% | -2.8% | +22.0% | +7.6% | +1.4% | -2.2% | +14.4% | – | |
| – | -4.0% | +6.3% | -5.9% | +11.2% | +2.4% | +5.7% | +9.1% | +22.1% | +22.4% | -9.4% | +13.1% | – | |
| – | +12.7% | -10.4% | +40.8% | -8.3% | +4.3% | -1.5% | +19.7% | +9.9% | +5.1% | -3.7% | +14.1% | – | |
| – | – | – | – | – | – | – | -143.4% | – | -7.5% | -446.1% | – | – | |
| – | +2.0% | +35.0% | -29.7% | +187.5% | +47.8% | 0.0% | +12.7% | -11.0% | +3.7% | +6.0% | +3.0% | – | |
| – | – | – | – | – | – | – | -148.5% | – | -21.7% | -586.6% | – | – | |
| – | -263.6% | – | – | – | -81.1% | +1,601.9% | -124.9% | – | -99.9% | -75.9% | +57.1% | – | |
| – | – | – | – | – | – | – | -147.3% | – | – | -530.8% | – | – | |
| – | – | – | – | – | – | – | -137.4% | – | -11.0% | -287.8% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.